PMC:7105881 / 47785-48557
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1529 | 9-17 | Species | denotes | MERS-CoV | Tax:1335626 |
| 1530 | 141-149 | Species | denotes | MERS-CoV | Tax:1335626 |
| 1531 | 496-504 | Species | denotes | MERS-CoV | Tax:1335626 |
| 1532 | 367-380 | Disease | denotes | CoV infection | MESH:D018352 |
| 1533 | 758-771 | Disease | denotes | CoV infection | MESH:D018352 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T251 | 371-380 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T252 | 762-771 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T600 | 104-110 | http://purl.obolibrary.org/obo/NCBITaxon_33208 | denotes | animal |
| T601 | 210-214 | http://purl.obolibrary.org/obo/CLO_0001185 | denotes | 2018 |
| T602 | 542-543 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32265848-27795425-36511196 | 191-195 | 27795425 | denotes | 2017 |
| 32265848-30058403-36511197 | 210-214 | 30058403 | denotes | 2018 |
| 32265848-25640653-36511199 | 414-418 | 25640653 | denotes | 2016 |
| 32265848-27795425-36511200 | 432-436 | 27795425 | denotes | 2017 |
| 32265848-28277821-36511201 | 454-458 | 28277821 | denotes | 2017 |
| 32265848-30646569-36511202 | 582-586 | 30646569 | denotes | 2019 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T267 | 0-216 | Sentence | denotes | Numerous MERS-CoV RBD-based subunit vaccines have been developed and extensively evaluated in available animal models since the emergence of MERS-CoV (Table 2) (Du et al., 2013c; Tai et al., 2017; Zhou et al., 2018). |
| T268 | 217-460 | Sentence | denotes | In general, these subunit vaccines have strong immunogenicity and are capable of inducing high neutralizing antibodies and/or protection against MERS-CoV infection (Ma et al., 2014b; Zhang et al., 2016; Tai et al., 2017; Wang Y. et al., 2017). |
| T269 | 461-588 | Sentence | denotes | Most subunit vaccines based on the MERS-CoV RBD have been described in detail in a previous review article (Zhou et al., 2019). |
| T270 | 589-772 | Sentence | denotes | In this section, we will briefly introduce these RBD-targeting MERS vaccines, and compare their functionality, antigenicity, immunogenicity, and protection against MERS-CoV infection. |
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T757 | 9-17 | SP_9 | denotes | MERS-CoV |
| T758 | 104-110 | NCBITaxon:33208 | denotes | animal |
| T759 | 141-149 | SP_9 | denotes | MERS-CoV |
| T760 | 264-278 | BV_15 | denotes | immunogenicity |
| T761 | 325-335 | GO:0042571 | denotes | antibodies |
| T762 | 362-370 | SP_9 | denotes | MERS-CoV |
| T763 | 496-504 | SP_9 | denotes | MERS-CoV |
| T764 | 652-656 | SP_9 | denotes | MERS |
| T765 | 714-728 | BV_15 | denotes | immunogenicity |
| T766 | 753-761 | SP_9 | denotes | MERS-CoV |
| T93526 | 9-17 | SP_9 | denotes | MERS-CoV |
| T91251 | 104-110 | NCBITaxon:33208 | denotes | animal |
| T62499 | 141-149 | SP_9 | denotes | MERS-CoV |
| T4614 | 264-278 | BV_15 | denotes | immunogenicity |
| T22946 | 325-335 | GO:0042571 | denotes | antibodies |
| T84916 | 362-370 | SP_9 | denotes | MERS-CoV |
| T96714 | 496-504 | SP_9 | denotes | MERS-CoV |
| T83092 | 652-656 | SP_9 | denotes | MERS |
| T28599 | 714-728 | BV_15 | denotes | immunogenicity |
| T10115 | 753-761 | SP_9 | denotes | MERS-CoV |